Drug-induced chylothorax as a rare pleural complication in dasatinib therapy for chronic myeloid leukaemia
J R Coll Physicians Edinb. 2024 Mar 14:14782715241237577. doi: 10.1177/14782715241237577. Online ahead of print.ABSTRACTChylothorax is a lymphatic chylous pleural effusion typically associated with traumatic (iatrogenic, non-iatrogenic) and non-traumatic (infections, malignancy, lymphatic disorders) aetiologies. Drug-induced chylothorax is uncommon and mostly reported in association with BCR-ABL tyrosine kinase inhibitor therapy.PMID:38486345 | DOI:10.1177/14782715241237577 (Source: Journal of the Royal College of Physicians of Edinburgh)
Source: Journal of the Royal College of Physicians of Edinburgh - March 15, 2024 Category: General Medicine Authors: Isaac Ks Ng Mamta Ruparel Esther Hl Chan Kay Leong Khoo Source Type: research
Physiologically based pharmacokinetic modeling of imatinib and N ‐desmethyl imatinib for drug–drug interaction predictions
AbstractThe first-generation tyrosine kinase inhibitor imatinib has revolutionized the development of targeted cancer therapy and remains among the frontline treatments, for example, against chronic myeloid leukemia. As a substrate of cytochrome P450 (CYP) 2C8, CYP3A4, and various transporters, imatinib is highly susceptible to drug –drug interactions (DDIs) when co-administered with corresponding perpetrator drugs. Additionally, imatinib and its main metaboliteN-desmethyl imatinib (NDMI) act as inhibitors of CYP2C8, CYP2D6, and CYP3A4 affecting their own metabolism as well as the exposure of co-medications. This work pr...
Source: CPT: Pharmacometrics and Systems Pharmacology - March 14, 2024 Category: Drugs & Pharmacology Authors: Helena Leonie Hanae Loer,
Christina Kovar,
Simeon R üdesheim,
Fatima Zahra Marok,
Laura Maria Fuhr,
Dominik Selzer,
Matthias Schwab,
Thorsten Lehr Tags: ARTICLE Source Type: research
A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia
Expert Opin Drug Saf. 2024 Mar 14. doi: 10.1080/14740338.2024.2331190. Online ahead of print.ABSTRACTINTRODUCTION: Since the introduction of first tyrosine kinase inhibitor(TKI) imatinib, treatment of chronic myeloid leukemia (CML) has reachedexcellent survival expectancies. Long survival rates bring about issuesregarding TKI safety.AREAS COVERED: The aim of this review is to compare the side effectsof current TKIs both in the first- and later lines and outline a safety andprofile of CML treatment. Seminal studies on TKIs and other newer drugs andextended follow-up of these studies, real-life data of each drug were useddur...
Source: Expert Opinion on Drug Safety - March 14, 2024 Category: Drugs & Pharmacology Authors: Deniz Özmen Duygu Demet Alpayd ın Muhammed Ali Saldo ğan Ahmet Emre E şkazan Source Type: research
Physiologically based pharmacokinetic modeling of imatinib and N ‐desmethyl imatinib for drug–drug interaction predictions
AbstractThe first-generation tyrosine kinase inhibitor imatinib has revolutionized the development of targeted cancer therapy and remains among the frontline treatments, for example, against chronic myeloid leukemia. As a substrate of cytochrome P450 (CYP) 2C8, CYP3A4, and various transporters, imatinib is highly susceptible to drug –drug interactions (DDIs) when co-administered with corresponding perpetrator drugs. Additionally, imatinib and its main metaboliteN-desmethyl imatinib (NDMI) act as inhibitors of CYP2C8, CYP2D6, and CYP3A4 affecting their own metabolism as well as the exposure of co-medications. This work pr...
Source: CPT: Pharmacometrics and Systems Pharmacology - March 14, 2024 Category: Drugs & Pharmacology Authors: Helena Leonie Hanae Loer,
Christina Kovar,
Simeon R üdesheim,
Fatima Zahra Marok,
Laura Maria Fuhr,
Dominik Selzer,
Matthias Schwab,
Thorsten Lehr Tags: ARTICLE Source Type: research
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Leukemia, Published online: 12 March 2024; doi:10.1038/s41375-024-02215-9Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF (Source: Leukemia)
Source: Leukemia - March 12, 2024 Category: Hematology Authors: Daniela Žáčková Luk áš Semerád Edgar Faber Hana Klamov á Luk áš Stejskal Petra B ělohlávková Michal Karas Eduard Cmunt Olga Černá Ji řina Procházková Petra Čičátková Ane žka Kvetková Tom áš Horňák Ivana Skoumalov á Dana Srbov Source Type: research
Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices
In conclusion, in Germany pts with CML are routinely monitored by qPCR and good responses are achieved in the majority. Treatment changes are mainly due to adverse events rather than suboptimal responses. (Source: Annals of Hematology)
Source: Annals of Hematology - March 12, 2024 Category: Hematology Source Type: research
Tyrosine Kinase Inhibitor-induced Cerebrovascular Occlusion Presenting with Moyamoya Disease-like Stenosis of the Circle of Willis
Intern Med. 2024 Mar 11. doi: 10.2169/internalmedicine.3337-23. Online ahead of print.ABSTRACTVascular occlusive events are notable adverse effects of tyrosine kinase inhibitors (TKIs), which are promising treatments for chronic myeloid leukemia (CML). We herein report the case of a patient with CML who developed cerebrovascular occlusion of the circle of Willis during TKI treatment. Our patient did not meet the diagnostic criteria for moyamoya disease due to the insignificant development of moyamoya vessels. The lack of moyamoya vessel development may be explained by the suppression of tyrosine kinases that are responsibl...
Source: Internal Medicine - March 10, 2024 Category: Internal Medicine Authors: Takuya Terakawa Yuya Hayasaka Yuka Umeki Mako Ikeda Yoshiki Matsuoka Masanari Mizuki Shogo Matsui Wataru Nakahara Hitomi Matsunaga Shayne Morris Takeo Nishida Takayuki Sakaki Takeshi Yoshimoto Shuji Ueda Source Type: research
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
CONCLUSION: Nilotinib, dasatinib and flumatinib had comparable efficacy, and significantly higher therapy responses and higher FFS rates than imatinib in newly diagnosed CML patients. However, there were no significant differences in PFS and OS among these 4 TKIs. These real-world data may provide additional evidence for routine clinical assessments to identify more appropriate therapies.PMID:38461040 | DOI:10.1016/j.clml.2024.02.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 9, 2024 Category: Cancer & Oncology Authors: Xiaoshuai Zhang Na Xu Yunfan Yang Hai Lin Bingcheng Liu Xin Du Xiaoli Liu Rong Liang Chunyan Chen Jian Huang Huanling Zhu Ling Pan Xiaodong Wang Guohui Li Zhuogang Liu Yanqing Zhang Zhenfang Liu Jianda Hu Chunshui Liu Fei Li Wei Yang Li Meng Yanqiu Han Li Source Type: research
